GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...
Wall Street Journal3d
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK GSK3.22%increase ... The British pharmaceutical giant said Wednesday that it had struck agreements with 10 plaintiff firms aimed at resolving 93%, or about 80,000, of pending Zantac lawsuits ...
FiercePharma3d
GSK will pony up $2.2B to resolve 80K Zantac cases
GSK has agreed to pay up to $2.2 billion to resolve ... The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S., most of which had been ...
Morningstar1mon
GSK Reaches Another Settlement in Zantac Litigation
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Reuters1mon
GSK's experimental herpes vaccine fails to meet main goal in trial
Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...
pharmaphorum5d
GSK finds synergies with global marketing strategy
GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...
中国日报网1mon
Pharmaceutical giant GSK vows more cutting-edge HIV treatment
People living with HIV and people with potential exposure to HIV in China are expected to leverage more of GlaxoSmithKline's innovative research results for the prevention and treatment of the ...
STAT29d
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...
Seeking Alpha28d
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...
Bloomberg L.P.1mon
GSK’s Herpes Shot Fails in Early Trial in Blow for Drugmaker
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...